Ischemic heart disease: 2005 Update;Actualización en cardiopatía isquémica 2005

Revista Espanola de Cardiologia

Volumn 59, Issue SUPPL.1, 2006, Pages 3-19

  Bardají, Alfredo ^a   Alonso, Joaquín ^b   García Moll, Xavier ^c   Bueno, Héctor ^d  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Acute coronary syndrome; Myocardial infarction; Pathophysiology; Prevention

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; AZITHROMYCIN; CARVEDILOL; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOPROLOL; RETEPLASE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADVENTITIA; ARTERIOSCLEROSIS; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REPERFUSION; REVIEW; ST SEGMENT; ST SEGMENT ELEVATION; VASA VASORUM;

EID: 34547645794     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13084444     Document Type: Article

References (87)

1. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974-5.
2. Taylor KE, Giddings JC, Van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2005;25:1225-30.
3. Trion A, De Maat MP, Jukema JW, Van der Laarse A, Maas MC, Offerman EH, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-Leiden/human Creactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635-40.
4. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 2005;25:1641-6.
5. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005;102:8309-14.
6. Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2005;112:1016-23.
7. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004;24:1509-15.
8. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004;50:574-81.
9. Kamimura M, Viedt C, Dalpke A, Rosenfeld ME, Mackman N, Cohen DM, et al. Interleukin-10 suppresses tissue factor expression in lipopolysaccharide- stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway. Circ Res. 2005;97:305-13.
10. Halvorsen B, Waehre T, Scholz H, Clausen OP, Von der Thusen JH, Muller F, et al. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res. 2005;46:211-9.
11. Domínguez Rodríguez A, Abreu González P, García González MJ, Ferrer Hita J. Asociación entre concentraciones séricas de interleucina 10 y desarrollo de insuficiencia cardíaca en pacientes con infarto agudo de miocardio tratados con angioplastia primaria. Rev Esp Cardiol. 2005;58:626-30.
12. Domínguez-Rodríguez A, Abreu-González P, De la Rosa A, Vargas M, Ferrer J, García M. Role of endogenous interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty interleukin-10 and primary angioplasty. Int J Cardiol. 2005;99:77-81.
13. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167-75.
14. Kawano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism. 2005;54:653-6.
15. Thamer C, Stefan N, Stumvoll M, Haring H, Fritsche A. Reduced adiponectin serum levels in smokers. Atherosclerosis. 2005;179:421-2.
16. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747-53.
17. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-61.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
19. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Hörkkö S, et al. The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. J Lipid Res. 2005;46:1353-63.
20. Ameli S, Hultgårdh-Nilsson A, Regnström J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL on early atherosclerosis in hypercholesterolemic rabbits. Arteriosclerosis, Thrombosis and Vascular Biology. 1996;16:1074-9.
21. Zhou X, Robertson AK, Mats Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circulation Res. 2005;96:427-34.
22. Hauer AD, Uyttenhove C, De Vos P, Stroobant V, Renauld JC, Van Berkel TJ, et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112:1054-62.
23. García-Moll X. Vacuna antigripal: ¿nuevas indicaciones de una vieja conocida? Rev Esp Cardiol. 2003;56:944-6.
24. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol. 2005;25:18-28.
25. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-8.
26. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44:1690-9.
27. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Rev Esp Cardiol. 2005;58:679-728.
28. Bueno H, Bardají A, Fernández-Ortiz A, Marrugat J, Martí H, Heras M. Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español). Rev Esp Cardiol. 2005;58:244-52.
29. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (euro Heart Survey ACS). Eur Heart J. 2002;23:1190-201.
30. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes. Results from the CRUSADE quality improvement initiative. JAMA. 2004;292:2096-104.
31. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2002;23:1809-40.
32. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-900.
33. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4.
34. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 2004;25:476-83.
35. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45:1392-6.
36. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, DiSciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) Study. Circulation. 2005;111:2099-106.
37. Boeynaems JM, Van Giezen H, Savi P, Herbert JM. P2Y receptor antagonists in thrombosis. Curr Opin Invest Drugs. 2005;6:275-82.
38. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al; JUMBO-TIMI 26 Investigators. A randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, to clopidogrel in percutaneous coronary intervention; results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-73.
39. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, Ten Berg JM, et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N Engl J Med. 2004;350:232-8.
40. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, Von Beckerath N, et al; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627-35.
41. Claeys MJ, Van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van der Goten P, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J. 2005;26:567-75.
42. Schomig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schuhlen H, et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005;26:1379-84.
43. Dalby M, Montalescot G, Bal dit Sollier C, Vicaut E, Soulat T, Collet JP, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43:162-8.
44. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-9.
45. Rasoul S. A comparison of dual versus triple antiplatelet therapy in patients with non ST segment elevation acute coronary syndromes. Results of the ELISA-2 trial. Presentado en el XXV Congreso de la European Society of Cardiology 2005. Estocolmo, 6 de septiembre de 2005.
46. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89-96.
47. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005;46:906-19.
48. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
49. Blazing MA, De Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et al; A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-STsegment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA. 2004;292:55-64.
50. Mehta S, Yusuf S. Efficacy and safety of fondaparinux compared to enoxaparin in 20,000 high risk patients with ACS without ST elevation: the OASIS 5 Michelangelo programme. Presentado en el XXV Congreso de la European Society of Cardiology 2005. Estocolmo, 5 de septiembre de 2005.
51. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.
52. Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, et al; REPLACE-2 Investigators. Lack of clopidogrel pre-treatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol. 2004;44:1194-9.
53. Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005;95:716-21.
54. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine versus selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of the randomized trials. JAMA. 2005;293:2908-17.
55. Biondi-Zoccai GGL, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte M, et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J. 2005;149:504-11.
56. Fox KAA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TRD, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366:914-20.
57. Schellekens S, Verheugt FW. Hotline sessions of the 26th European Congress of Cardiology. Eur Heart J. 2004;25:2164-6.
58. Sans S, Puigdefábregas A, Paluzie G, Monterde D, Balaguer-Vintro I. Increasing trends of acute myocardial infarction in Spain: the MONICA-Catalonia Study. Eur Heart J. 2005;26:505-15.
59. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89.
60. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with st-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY Study. JAMA. 2005;294:1224-32.
61. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61.
62. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al. Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial. JAMA. 2005;293:437-46.
63. Ohman EM, Van de Werf F, Antman EM, Califf RM, De Lemos JA, Gibson CM, et al. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial. Am Heart J. 2005;150:79-88.
64. Steg PG, Francois L, Iung B, Himbert D, Aubry P, Charlier P, et al. Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. Eur Heart J. 2005;26:1831-7.
65. Suryapranata H, De Luca G, Van't Hof AWJ, Ottervanger JP, Hoorntje JCA, Dambrink JHA. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart. 2005;91:641-5.
66. Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865-72.
67. Thiele H, Engelmann L, Elsner K, Kappl MJ, Storch WH, Rahimi K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26:1956-63.
68. Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005;46:417-24.
69. Mehta RH, Granger CB, Alexander CP, Bossone E, White HD, Sketch Jr MH. Reperfusion strategies for acute myocardial infarction in the elderly. Benefits and risks. J Am Coll Cardiol. 2005;45:471-8.
70. Cequier A, Bueno H, Augé JM, Bardaji A, Fernández-Ortiz A, Heras M. Características y mortalidad del infarto agudo de miocardio tratado con intervencionismo coronario percutáneo primario en España. Resultados del registro TRIANA1. Rev Esp Cardiol. 2005;58:341-50.
71. Bardají A, Bueno H, Fernández-Ortiz A, Cequier A, Augé JM, Heras M. Características clínicas, tratamiento y evolución del infarto agudo de miocardio en ancianos tratados médicamente. Resultados del registro TRIANA 2. Rev Esp Cardiol. 2005;58:351-8.
72. Bueno H, Martínez-Selles M, Pérez-David E, López-Palop R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur Heart J. 2005;26:1705-11.
73. De Luca G, Van't Hof AWJ, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JHE, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005;26:662-6.
74. Grines, C. SENIOR PAMI. A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. TCT 2005; October 16-21, 2005; Washington, DC.
75. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. Randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
76. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149:565-72.
77. Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J. 2005;150:54-78.
78. Powell LH, Catellier D, Freedland KE, Burg MM, Woods SL, Bittner V, et al. Depression and heart failure in patients with a new myocardial infarction. Am Heart J. 2005;149:851-5.
79. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-54.
80. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-45.
81. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611-6.
82. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
83. Stone PH, Lloyd-Jones DM, Kinlay S, Frei B, Carlson W, Rubenstein J, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation. 2005;111:1747-55.
84. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velázquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-8.
85. Pitt B, White H, Nicolau J, Martínez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-31.
86. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, López-Sendón J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525-30.
87. Andreotti F, Testa L, Biondi-Zoccai G, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J [serie en Internet] 2005 september [citado 5 Sept 2005].